Academic Journal
أعرض في EDS

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.

التفاصيل البيبلوغرافية
العنوان: R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
المؤلفون: Federico, M, Luminari, S, Dondi, A, Tucci, A, Vitolo, U, Rigacci, L, Di Raimondo, F, Carella, AM, Pulsoni, A, Merli, F, Arcaini, L, Angrilli, F, Stelitano, C, Gaidano, G, Dell'olio, M, Marcheselli, L, Galimberti, S, Sacchi, S, Brugiatelli, M., FRANCO, Vito
المساهمون: Federico, M, Luminari, S, Dondi, A, Tucci, A, Vitolo, U, Rigacci, L, Di Raimondo, F, Carella, AM, Pulsoni, A, Merli, F, Arcaini, L, Angrilli, F, Stelitano, C, Gaidano, G, Dell'olio, M, Marcheselli, L, Franco, V, Galimberti, S, Sacchi, S, Brugiatelli, M.
بيانات النشر: US
سنة النشر: 2013
المجموعة: IRIS Università degli Studi di Palermo
مصطلحات موضوعية: NON-HODGKINS-LYMPHOMAS, 1ST-LINE TREATMENT, RESPONSE CRITERIA, CLINICAL-TRIALS, PHASE-III, CHEMOTHERAPY, RITUXIMAB, FLUDARABINE, CYCLOPHOSPHAMIDE, VINCRISTINE
الوصف: PURPOSE: Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. PATIENTS AND METHODS: We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). RESULTS: There were 534 patients enrolled onto the study. Overall response rates were 88%, 93%, and 91% for R-CVP, R-CHOP, and R-FM, respectively (P=.247). After a median follow-up of 34 months, 3-year TTFs were 46%, 62%, and 59% for the respective treatment groups (R-CHOP v R-CVP, P=.003; R-FM v R-CVP, P=.006; R-FM v R-CHOP, P=.763). Three-year progression-free survival (PFS) rates were 52%, 68%, and 63% (overall P=.011), respectively, and 3-year overall survival was 95% for the whole series. R-FM resulted in higher rates of grade 3 to 4 neutropenia (64%) compared with R-CVP (28%) and R-CHOP (50%; P< .001). Overall, 23 second malignancies were registered during follow-up: four in R-CVP, five in R-CHOP, and 14 in R-FM.
نوع الوثيقة: article in journal/newspaper
اللغة: English
Relation: info:eu-repo/semantics/altIdentifier/wos/WOS:000317831500012; volume:31; issue:12; firstpage:1506; lastpage:1513; numberofpages:8; journal:JOURNAL OF CLINICAL ONCOLOGY; http://hdl.handle.net/10447/97426
الاتاحة: http://hdl.handle.net/10447/97426
Rights: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.CD36409B
قاعدة البيانات: BASE
ResultId 1
Header edsbas
BASE
edsbas.CD36409B
845
3
Academic Journal
academicJournal
845.314270019531
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsbas&AN=edsbas.CD36409B&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => http://hdl.handle.net/10447/97426# [Name] => EDS - BASE [Category] => fullText [Text] => View record in BASE [MouseOverText] => View record in BASE ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => &lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Federico%2C+M%22&quot;&gt;Federico, M&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Luminari%2C+S%22&quot;&gt;Luminari, S&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dondi%2C+A%22&quot;&gt;Dondi, A&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Tucci%2C+A%22&quot;&gt;Tucci, A&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Vitolo%2C+U%22&quot;&gt;Vitolo, U&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Rigacci%2C+L%22&quot;&gt;Rigacci, L&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Di+Raimondo%2C+F%22&quot;&gt;Di Raimondo, F&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Carella%2C+AM%22&quot;&gt;Carella, AM&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Pulsoni%2C+A%22&quot;&gt;Pulsoni, A&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Merli%2C+F%22&quot;&gt;Merli, F&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Arcaini%2C+L%22&quot;&gt;Arcaini, L&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Angrilli%2C+F%22&quot;&gt;Angrilli, F&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Stelitano%2C+C%22&quot;&gt;Stelitano, C&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Gaidano%2C+G%22&quot;&gt;Gaidano, G&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Dell&#39;olio%2C+M%22&quot;&gt;Dell&#39;olio, M&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Marcheselli%2C+L%22&quot;&gt;Marcheselli, L&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Galimberti%2C+S%22&quot;&gt;Galimberti, S&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Sacchi%2C+S%22&quot;&gt;Sacchi, S&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22Brugiatelli%2C+M%2E%22&quot;&gt;Brugiatelli, M.&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;AR&quot; term=&quot;%22FRANCO%2C+Vito%22&quot;&gt;FRANCO, Vito&lt;/searchLink&gt; )
Array ( [Name] => Author [Label] => Contributors [Group] => Au [Data] => Federico, M&lt;br /&gt;Luminari, S&lt;br /&gt;Dondi, A&lt;br /&gt;Tucci, A&lt;br /&gt;Vitolo, U&lt;br /&gt;Rigacci, L&lt;br /&gt;Di Raimondo, F&lt;br /&gt;Carella, AM&lt;br /&gt;Pulsoni, A&lt;br /&gt;Merli, F&lt;br /&gt;Arcaini, L&lt;br /&gt;Angrilli, F&lt;br /&gt;Stelitano, C&lt;br /&gt;Gaidano, G&lt;br /&gt;Dell&#39;olio, M&lt;br /&gt;Marcheselli, L&lt;br /&gt;Franco, V&lt;br /&gt;Galimberti, S&lt;br /&gt;Sacchi, S&lt;br /&gt;Brugiatelli, M. )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => US )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2013 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => IRIS Universit&#224; degli Studi di Palermo )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => &lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22NON-HODGKINS-LYMPHOMAS%22&quot;&gt;NON-HODGKINS-LYMPHOMAS&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%221ST-LINE+TREATMENT%22&quot;&gt;1ST-LINE TREATMENT&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22RESPONSE+CRITERIA%22&quot;&gt;RESPONSE CRITERIA&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CLINICAL-TRIALS%22&quot;&gt;CLINICAL-TRIALS&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22PHASE-III%22&quot;&gt;PHASE-III&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CHEMOTHERAPY%22&quot;&gt;CHEMOTHERAPY&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22RITUXIMAB%22&quot;&gt;RITUXIMAB&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22FLUDARABINE%22&quot;&gt;FLUDARABINE&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22CYCLOPHOSPHAMIDE%22&quot;&gt;CYCLOPHOSPHAMIDE&lt;/searchLink&gt;&lt;br /&gt;&lt;searchLink fieldCode=&quot;DE&quot; term=&quot;%22VINCRISTINE%22&quot;&gt;VINCRISTINE&lt;/searchLink&gt; )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => PURPOSE: Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. PATIENTS AND METHODS: We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). RESULTS: There were 534 patients enrolled onto the study. Overall response rates were 88%, 93%, and 91% for R-CVP, R-CHOP, and R-FM, respectively (P=.247). After a median follow-up of 34 months, 3-year TTFs were 46%, 62%, and 59% for the respective treatment groups (R-CHOP v R-CVP, P=.003; R-FM v R-CVP, P=.006; R-FM v R-CHOP, P=.763). Three-year progression-free survival (PFS) rates were 52%, 68%, and 63% (overall P=.011), respectively, and 3-year overall survival was 95% for the whole series. R-FM resulted in higher rates of grade 3 to 4 neutropenia (64%) compared with R-CVP (28%) and R-CHOP (50%; P&lt; .001). Overall, 23 second malignancies were registered during follow-up: four in R-CVP, five in R-CHOP, and 14 in R-FM. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article in journal/newspaper )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => info:eu-repo/semantics/altIdentifier/wos/WOS:000317831500012; volume:31; issue:12; firstpage:1506; lastpage:1513; numberofpages:8; journal:JOURNAL OF CLINICAL ONCOLOGY; http://hdl.handle.net/10447/97426 )
Array ( [Name] => URL [Label] => Availability [Group] => URL [Data] => http://hdl.handle.net/10447/97426 )
Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => info:eu-repo/semantics/openAccess )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsbas.CD36409B )
RecordInfo Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => English ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => NON-HODGKINS-LYMPHOMAS [Type] => general ) [1] => Array ( [SubjectFull] => 1ST-LINE TREATMENT [Type] => general ) [2] => Array ( [SubjectFull] => RESPONSE CRITERIA [Type] => general ) [3] => Array ( [SubjectFull] => CLINICAL-TRIALS [Type] => general ) [4] => Array ( [SubjectFull] => PHASE-III [Type] => general ) [5] => Array ( [SubjectFull] => CHEMOTHERAPY [Type] => general ) [6] => Array ( [SubjectFull] => RITUXIMAB [Type] => general ) [7] => Array ( [SubjectFull] => FLUDARABINE [Type] => general ) [8] => Array ( [SubjectFull] => CYCLOPHOSPHAMIDE [Type] => general ) [9] => Array ( [SubjectFull] => VINCRISTINE [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Federico, M ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Luminari, S ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dondi, A ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Tucci, A ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Vitolo, U ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rigacci, L ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Di Raimondo, F ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Carella, AM ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pulsoni, A ) ) ) [9] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Merli, F ) ) ) [10] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Arcaini, L ) ) ) [11] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Angrilli, F ) ) ) [12] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Stelitano, C ) ) ) [13] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Gaidano, G ) ) ) [14] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dell'olio, M ) ) ) [15] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Marcheselli, L ) ) ) [16] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Galimberti, S ) ) ) [17] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sacchi, S ) ) ) [18] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Brugiatelli, M. ) ) ) [19] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => FRANCO, Vito ) ) ) [20] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Federico, M ) ) ) [21] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Luminari, S ) ) ) [22] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dondi, A ) ) ) [23] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Tucci, A ) ) ) [24] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Vitolo, U ) ) ) [25] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Rigacci, L ) ) ) [26] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Di Raimondo, F ) ) ) [27] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Carella, AM ) ) ) [28] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Pulsoni, A ) ) ) [29] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Merli, F ) ) ) [30] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Arcaini, L ) ) ) [31] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Angrilli, F ) ) ) [32] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Stelitano, C ) ) ) [33] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Gaidano, G ) ) ) [34] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Dell'olio, M ) ) ) [35] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Marcheselli, L ) ) ) [36] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Franco, V ) ) ) [37] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Galimberti, S ) ) ) [38] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sacchi, S ) ) ) [39] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Brugiatelli, M. ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 01 [Type] => published [Y] => 2013 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-locals [Value] => edsbas ) [1] => Array ( [Type] => issn-locals [Value] => edsbas.oa ) ) ) ) ) ) )
IllustrationInfo